Three companies in the healthcare sector, French diagnostics company BioMérieux and German laboratories Evotech and Boehringer Ingelheim, will form a joint venture to find new antibiotics in the face of the growing problem of antibiotic resistance.
This new Lyon-based company, Aurobac Therapeutics, will be responsible for developing a new clinical approach from diagnosis to treatment, they said in a joint press release on Wednesday.
Aurobac is funded with 30 million euros by Boehringer Ingelheim and 5 million euros each by Evotec and bioMérieux.
Its aim is to fight against antibiotic resistance, which is a major threat today. By various mechanisms, antibiotics, which represent the majority of drugs in circulation, gradually lose their effectiveness against bacteria.
The overconsumption of these treatments in human health and their overuse in animal health are particularly isolated to explain the phenomenon.
Every year in the EU, 25,000 people die from antibiotic resistance, according to European officials.
Conventional surgical interventions such as caesarean sections or hip prosthesis implants, for example, can endanger the patient’s life, the press release said.
Aurobac will work to develop a strategy related to current therapies based on approaches using broad-spectrum and non-targeted antibiotics.
Its aim is to develop new targeted solutions related to rapid diagnosis, especially tests that allow the rapid identification of pathogens and their resistance profiles, the companies said.
/ats
“Avid gamer. Social media geek. Proud troublemaker. Thinker. Travel fan. Problem solver.”